Research Report On Global And China Human Vaccine Industry, 2013-2017
The
research object of the report is human vaccines. According to different
types and sources, vaccines can be divided into pathogenic protein
vaccine, recombinant protein vaccines, immune protein vaccines and gene
vaccines.
To Read The Complete Report with TOC :
In
China, vaccines are generally divided into Vaccine I and Vaccine II.
Vaccine I is offered for free, and it's priced and purchased uniformly
by the government, covering the major epidemic diseases of Hepatitis B,
epidemic cerebrospinal meningitis, Tetanus, etc. Vaccine II is other
vaccines inoculated voluntarily at residents' own expense. It is
independently priced and has large profit margins, but there are intense
competition in the market. The frequentlyused Vaccine II includes
Pneumonia vaccine, Varicella Vaccine, Type B Haemophilus Influenzae
Conjugate Vaccine, Influenza Vaccine, Rabies Vaccine and so on. In
China, Vaccine I market are occupied by stateowned enterprises, while
foreignfunded enterprises and private enterprises have certain
advantages in Vaccine II market.
In
2012, the scale of Chinese vaccine market was about CNY 19 billion,
while the scale of pharmaceutical industry was about CNY 1.78 trillion
in the same period. The sales revenue of Chinese vaccine industry was
only about 1% of that of the pharmaceutical industry far below the
global average level of 3%, estimated by CRI. There is still much space
for growth.
To Buy a Copy Of This Report:-
China
has the largest population in the world with 10 million newborns
yearly. Meanwhile, the aging of the society is increasingly serious.
With the economic development and increasingly frequent population
immigrations, it inevitably widens the spreading range and increases the
speed of disease spreading. Accordingly, new epidemic diseases (Avian
Influenza, Influenza A H1N1 and so on) occur frequently.
Contact:-
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
No comments:
Post a Comment